Literature DB >> 18480324

Processing of Clostridium difficile toxins.

Torsten Giesemann1, Martina Egerer1, Thomas Jank1, Klaus Aktories1.   

Abstract

The pathogenicity of Clostridium difficile depends on the large clostridial glucosylating toxins A and B (TcdA and TcdB). The proteins accomplish their own uptake by a modular structure comprising a catalytic and a binding/translocation domain. Based on a proteolytic processing step solely the catalytic domain reaches the cytosol. Within the cells, the glucosyltransferases inactivate small GTPases by mono-O-glucosylation. Here, a short overview is given regarding latest insights into the intramolecular processing, which is mediated by an intrinsic protease activity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18480324     DOI： 10.1099/jmm.0.47742-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN： 0022-2615            Impact factor:   2.472


  20 in total

1.  Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB.

Authors:  Aaron W Puri; Patrick J Lupardus; Edgar Deu; Victoria E Albrow; K Christopher Garcia; Matthew Bogyo; Aimee Shen
Journal:  Chem Biol       Date:  2010-11-24

2.  CPDadh: a new peptidase family homologous to the cysteine protease domain in bacterial MARTX toxins.

Authors:  Jimin Pei; Patrick J Lupardus; K Christopher Garcia; Nick V Grishin
Journal:  Protein Sci       Date:  2009-04       Impact factor: 6.725

3.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

4.  Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.

Authors:  Shan Li; Lianfa Shi; Zhiyong Yang; Yongrong Zhang; Gregorio Perez-Cordon; Tuxiong Huang; Jeremy Ramsey; Numan Oezguen; Tor C Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

5.  Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol.

Authors:  Shan Li; Lianfa Shi; Zhiyong Yang; Hanping Feng
Journal:  Pathog Dis       Date:  2013-01-14       Impact factor: 3.166

Review 6.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

7.  Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.

Authors:  Jinfu Xie; Julie Zorman; Lani Indrawati; Melanie Horton; Keri Soring; Joseph M Antonello; Yuhua Zhang; Susan Secore; Matthew Miezeiewski; Su Wang; Anthony D Kanavage; Julie M Skinner; Irene Rogers; Jean-Luc Bodmer; Jon H Heinrichs
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

8.  Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms.

Authors:  Nicole M Chumbler; Melissa A Farrow; Lynne A Lapierre; Jeffrey L Franklin; D Borden Lacy
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

9.  Disruption of intrinsic motions as a mechanism for enzyme inhibition.

Authors:  Rebecca J Swett; G Andrés Cisneros; Andrew L Feig
Journal:  Biophys J       Date:  2013-07-16       Impact factor: 4.033

10.  Mechanistic and structural insights into the proteolytic activation of Vibrio cholerae MARTX toxin.

Authors:  Aimee Shen; Patrick J Lupardus; Victoria E Albrow; Andrew Guzzetta; James C Powers; K Christopher Garcia; Matthew Bogyo
Journal:  Nat Chem Biol       Date:  2009-07       Impact factor: 15.040
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.